Relay Therapeutics (RLAY) Projected to Post Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Relay Therapeutics to announce earnings of ($0.3911) per share and revenue of $0.96 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. On average, analysts expect Relay Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relay Therapeutics Stock Performance

Relay Therapeutics stock opened at $19.54 on Wednesday. The company has a 50 day moving average price of $17.38 and a 200 day moving average price of $13.27. Relay Therapeutics has a 52 week low of $3.03 and a 52 week high of $20.79. The firm has a market capitalization of $3.74 billion, a price-to-earnings ratio of -12.45 and a beta of 1.69.

Insider Buying and Selling at Relay Therapeutics

In other Relay Therapeutics news, insider Donald A. Bergstrom sold 2,237 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $18.61, for a total transaction of $41,630.57. Following the transaction, the insider directly owned 407,660 shares of the company’s stock, valued at $7,586,552.60. This represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Thomas Catinazzo sold 1,459 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $18.61, for a total value of $27,151.99. Following the transaction, the chief financial officer owned 158,285 shares in the company, valued at approximately $2,945,683.85. This trade represents a 0.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 427,356 shares of company stock valued at $7,461,240. 5.04% of the stock is currently owned by insiders.

Institutional Trading of Relay Therapeutics

Large investors have recently made changes to their positions in the stock. Commodore Capital LP bought a new position in shares of Relay Therapeutics in the 2nd quarter valued at approximately $46,191,000. Bellevue Group AG grew its holdings in Relay Therapeutics by 1.4% during the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock valued at $43,564,000 after purchasing an additional 114,740 shares during the last quarter. State Street Corp grew its holdings in Relay Therapeutics by 26.8% during the fourth quarter. State Street Corp now owns 6,426,111 shares of the company’s stock valued at $54,365,000 after purchasing an additional 1,360,121 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Relay Therapeutics by 11.6% in the fourth quarter. Geode Capital Management LLC now owns 3,409,363 shares of the company’s stock valued at $28,849,000 after purchasing an additional 354,777 shares during the period. Finally, Millennium Management LLC raised its position in shares of Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock valued at $7,710,000 after purchasing an additional 374,491 shares during the period. Institutional investors own 96.98% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Raymond James Financial restated a “strong-buy” rating on shares of Relay Therapeutics in a report on Tuesday, May 19th. UBS Group set a $26.00 price objective on Relay Therapeutics in a research note on Tuesday, May 19th. Guggenheim lifted their target price on Relay Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Oppenheimer increased their price target on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 28th. Finally, Zacks Research cut shares of Relay Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.92.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.